Recce Pharmaceuticals

Announcements

News and Media

Corporate Governance

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

MST Access.pdf

Recce Pharmaceuticals (RCE.AX) | Analyst: Chris Kallos, CFA

Update Note – Expanding Phase 1/2 UTI IV Study – Ethics Approval Received

-     HREC approves expanding intravenous trial in urinary tract infections (UTIs) for R327

-     Scientia Clinical Research (NSW) joining present dosing at CMAX (SA)

-     Recce expects this development to expedite trial progress

Expansion of trial receives ethics approval: Recce Pharmaceuticals has announced that it has received Human Research Ethics Committee (HREC) approval to expand its Phase 1/2 UTI trial, assessing lead asset RECCE® 327 (R327) at more rapid IV administration rates. Recce sees this administration as potentially applicable when a patient first presents at a GP or acute care facility.

MST Access Updated Equities Research Report